title: Impact of metabolic syndrome on coronary patency after  thrombolytic therapy for acute myocardial infarction.
abstract: OBJECTIVE
  The metabolic syndrome (MS) is highly prevalent in patients with acute myocardial infarction. It has been shown that MS is associated with poor in-hospital outcome and long-term survival in patients with acute myocardial infarction. We aimed to investigate the effect of MS on the infarct-related artery patency in patients treated with thrombolytic therapy for acute myocardial infarction.
  
  
  METHODS
  We retrospectively analyzed 116 patients who were admitted to our clinics with acute ST elevation myocardial infarction and received thrombolytic therapy within 12 h of chest pain. MS was diagnosed according to National Cholesterol Education Program Adult Treatment Panel III criteria. The flow in the infarct-related artery was analyzed according to the thrombolysis in myocardial infarction (TIMI) flow grade and corrected TIMI frame count.
  
  
  RESULTS
  MS was present in 55.2% of patients. The proportion of patients with MS who achieved TIMI grade 3 f low after thrombolysis was significantly lower than that of patients without MS (41.5 vs. 58.5%, P < 0.001). Moreover, corrected TIMI frame counts were significantly higher inpatients with MS (58.3+/-34.8 vs. 44.7+/-28.1, P =0.02). On multivariate logistic regression analysis MS was the only independent predictor of TIMI flow less than 3 (P =0.03,odds ratio = 3.545, 95% confidence interval: 1.064-11.808).
  
  
  CONCLUSIONS
  We have shown for the first time that patients with MS have lower rates of TIMI grade 3 flow and higher corrected TIMI frame counts after thrombolytic therapy for acute myocardial infarction.
authors.affiliation: Department of Cardiology, Ataturk Education and Research Hospital, Ankara, Turkey. drasaatciyasar@yahoo.com
authors.forename: Ayse Saatci
authors.initials: AS
authors.lastname: Yasar
authors.forename: Emine
authors.initials: E
authors.lastname: Bilen
authors.forename: Mehmet
authors.initials: M
authors.lastname: Bilge
authors.forename: Ugur
authors.initials: U
authors.lastname: Arslantas
authors.forename: Fatih
authors.initials: F
authors.lastname: Karakas
mesh_terms: D000368:Aged; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D003326:Coronary Circulation; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications* / Q000503:physiopathology; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016017:Odds Ratio; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013300:Streptokinase / Q000008:administration & dosage; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D016896:Treatment Outcome; D014654:Vascular Patency
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D013300:Streptokinase; D010959:Tissue Plasminogen Activator